CARDIOMETABOLIC HEALTH CONGRESS

Diabetes

Digital Education Hubs

Once thought to be purely an endocrine disorder, a more modern understanding of insulin resistance and glycemic regulation has revealed that prediabetes, type 1 and type 2 diabetes are hugely related to cardiometabolic disease and its many comorbidities. As the understanding of how diabetes is related to conditions like obesity and heart failure grows, more therapeutic targets are being identified, showing promise for many new treatments.

CME/CE Activities

Diabetes

CGM – GOING BEYOND HBA1C TO OPTIMIZE AND INDIVIDUALIZE T2D MANAGEMENT

Diabetes

Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk

News Digest

Diabetes

Kidney Week 2023: Top Ten Takeaways

More than 12,000 attendees flocked to Philadelphia, Pennsylvania, on Nov. 2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease.

Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health

Learners who complete the Foundations of Cardiometabolic Health Certificate Course offered by Cardiometabolic Health Congress are now eligible to sit for a certification exam to

Cardiovascular Disease

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Dr. Salvatore Carbone is professor in the Department of Kinesiology & Health Sciences, College of Humanities & Sciences at the Virginia Commonwealth University. Can you

Cardiometabolic Health Congress (CMHC) Launches Focused Digital Education Hubs

Cardiometabolic health education leader CMHC announced that its digital education has been streamlined into 12 hubs organized by therapeutic or clinical topics for focused learning

Cardiometabolic Health Congress Hosts 2023 Women’s Masterclass in California

In August 2023, Cardiometabolic Health Congress will host the annual Women’s Cardiometabolic Health and Wellness Masterclass at the Laguna Cliffs Marriott Resort & Spa Informed

Atherosclerosis/Thrombosis

Care in (un)Common Settings with Dr. Keith C. Ferdinand

Cardiometabolic Health Congress (CMHC) sat down with Dr. Keith C. Ferdinand, the Gerald S. Berenson Endowed Chair in preventive cardiology at Tulane School of Medicine

Day 4 Nightly News: 18th Annual CMHC

On Saturday, Oct. 21, 2023, Cardiometabolic Health Congress (CMHC) celebrated the final day of its 18th Annual Conference, Social Determinants and Digital Advances in Cardiorenal

Day 3 Nightly News: 18th Annual CMHC

The third day of Social Determinants and Digital Advances in Cardiorenal Metabolic Health, the 18th Annual Cardiometabolic Health Congress (CMHC), delivered insights on selecting and

Day 2 Nightly News: 18th Annual CMHC

The cardiorenal metabolic education continued on Thursday, Oct. 19, 2023, when the 18th Annual Cardiometabolic Health Congress (CMHC) launched its second day of sessions at

Day 1 Preconference Nightly News: 18th Annual CMHC

On Wednesday, Oct. 18, 2023, Cardiometabolic Health Congress (CMHC) returned to the Boston Park Plaza for the 18th Annual Conference, Social Determinants and Digital Advances

Why Should We Use CGM in Patients With Type 2 Diabetes?

This clinical brief was developed from a session at the 17th Annual Cardiometabolic Health Congress (CMHC) presented by Irl B Hirsch, MD from the University

Should Diabetes Management be More Adipose-Centric?

This complimentary activity was developed by Neha Agarwal, PhD, Senior Clinical Manager for Cardiometabolic Health Congress (CMHC). It is supported by an educational grant from Lilly

FDA Approves First SGLT1/SGLT2 Inhibitor Sotagliflozin

The U.S. Food and Drug Administration (FDA) announced on May 26, 2023, it had approved the once-daily oral tablet sotagliflozin to reduce the risk of

10 Cardiorenal Stories to Watch

The experts behind Cardiometabolic Health Congress have identified 10 stories in cardiorenal medicine to watch in 2023.

Sanofi Joins Lilly and Novo to Cut Insulin Prices

Sanofi was the last of three pharmaceutical goliaths to announce they’d make good on their long-spoken promise to lower the price of their insulin.

Genetics Link Migraine and Blood Sugar

Research published on Feb. 20, 2023, by Rafiqul Islam, PhD, and colleagues from Queensland University of Technology may have uncovered a concrete link between blood

Lilly Cuts Insulin Prices

In an era when health care and pharmaceutical prices continue to trend upwards, Eli Lilly made a historic announcement on Wednesday, March 1, 2023, stating

Tirzepatide For Weight Loss

Eli LIlly’s tirzepatide (Monjaro) could become the most popular weight-loss drug ever if approved, but there are significant concerns about if it will be affordable